RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics Statistics
Share Statistics
RAPT Therapeutics has 132.01M shares outstanding. The number of shares has increased by 0.46% in one year.
| Shares Outstanding | 132.01M |
| Shares Change (YoY) | 0.46% |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | 76.6% |
| Shares Floating | 68.9M |
| Failed to Deliver (FTD) Shares | 8.12K |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 2.64M, so 2% of the outstanding shares have been sold short.
| Short Interest | 2.64M |
| Short % of Shares Out | 2% |
| Short % of Float | 3.27% |
| Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -8.16 and the forward PE ratio is -0.57. RAPT Therapeutics's PEG ratio is -0.39.
| PE Ratio | -8.16 |
| Forward PE | -0.57 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 6.48 |
| P/FCF Ratio | -9.7 |
| PEG Ratio | -0.39 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for RAPT Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.05.
| Current Ratio | 7.41 |
| Quick Ratio | 7.41 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.49 |
| Cash Flow / Debt | -14.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -82.54%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.67% |
| Return on Capital (ROIC) | -82.54% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.67M |
| Employee Count | 70 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -87.42% in the last 52 weeks. The beta is 0.03, so RAPT Therapeutics's price volatility has been higher than the market average.
| Beta | 0.03 |
| 52-Week Price Change | -87.42% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 2.18 |
| Relative Strength Index (RSI) | 44.58 |
| Average Volume (20 Days) | 3.4M |
Income Statement
| Revenue | n/a |
| Gross Profit | -3.55M |
| Operating Income | -127.06M |
| Net Income | -116.8M |
| EBITDA | -125.85M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.05 |
Balance Sheet
The company has 47.48M in cash and 6.91M in debt, giving a net cash position of 40.57M.
| Cash & Cash Equivalents | 47.48M |
| Total Debt | 6.91M |
| Net Cash | 40.57M |
| Retained Earnings | -484.68M |
| Total Assets | 108.47M |
| Working Capital | 92.24M |
Cash Flow
In the last 12 months, operating cash flow was -97.05M and capital expenditures -1.13M, giving a free cash flow of -98.17M.
| Operating Cash Flow | -97.05M |
| Capital Expenditures | -1.13M |
| Free Cash Flow | -98.17M |
| FCF Per Share | -2.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RAPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -269.91% |
| FCF Yield | -65.81% |
Analyst Forecast
The average price target for RAPT is $4, which is 254% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 254% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -2.64 |
| Piotroski F-Score | 3 |